PURPOSE: There is accumulating evidence that microRNAs may function like classic tumor suppressor genes but little is known about their mechanism of inactivation in cancer cells. We investigated whether somatic mutations are a common mechanism of inactivation of microRNA genes in ovarian cancer. EXPERIMENTAL DESIGN: Ten cancer-implicated microRNA genes were analyzed for somatic mutations in 90 ovarian epithelial cancers and matching normal DNA. High-resolution melt analysis and bidirectional sequencing was used to detect sequence variations. RESULTS: High-resolution melt analysis and direct sequencing did not identify any somatic mutations but did reveal numerous novel and previously reported germ line base substitutions, deletions, and insertions surrounding the mature microRNA sequences. The majority of variants were detected in the same proportion of non-cancer control individuals suggesting that they do not represent ovarian cancer-predisposing alleles. CONCLUSION: The absence of somatic mutations in any of the 10 cancer-implicated microRNAs in our large cohort of ovarian tumors suggests that this may be an uncommon mechanism of inactivation of microRNAs in ovarian cancer.
PURPOSE: There is accumulating evidence that microRNAs may function like classic tumor suppressor genes but little is known about their mechanism of inactivation in cancer cells. We investigated whether somatic mutations are a common mechanism of inactivation of microRNA genes in ovarian cancer. EXPERIMENTAL DESIGN: Ten cancer-implicated microRNA genes were analyzed for somatic mutations in 90 ovarian epithelial cancers and matching normal DNA. High-resolution melt analysis and bidirectional sequencing was used to detect sequence variations. RESULTS: High-resolution melt analysis and direct sequencing did not identify any somatic mutations but did reveal numerous novel and previously reported germ line base substitutions, deletions, and insertions surrounding the mature microRNA sequences. The majority of variants were detected in the same proportion of non-cancer control individuals suggesting that they do not represent ovarian cancer-predisposing alleles. CONCLUSION: The absence of somatic mutations in any of the 10 cancer-implicated microRNAs in our large cohort of ovarian tumors suggests that this may be an uncommon mechanism of inactivation of microRNAs in ovarian cancer.
Authors: Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson Journal: Cancer Res Date: 2010-02-23 Impact factor: 12.701
Authors: N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef Journal: Br J Cancer Date: 2010-03-30 Impact factor: 7.640
Authors: Chad J Creighton; Anadulce Hernandez-Herrera; Anders Jacobsen; Douglas A Levine; Parminder Mankoo; Nikolaus Schultz; Ying Du; Yiqun Zhang; Erik Larsson; Robert Sheridan; Weimin Xiao; Paul T Spellman; Gad Getz; David A Wheeler; Charles M Perou; Richard A Gibbs; Chris Sander; D Neil Hayes; Preethi H Gunaratne Journal: PLoS One Date: 2012-03-29 Impact factor: 3.240
Authors: Sally J Davis; David Y H Choong; Manasa Ramakrishna; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe Journal: BMC Cancer Date: 2011-05-17 Impact factor: 4.430
Authors: Georgina L Ryland; Jennifer L Bearfoot; Maria A Doyle; Samantha E Boyle; David Y H Choong; Simone M Rowley; Richard W Tothill; Kylie L Gorringe; Ian G Campbell Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240
Authors: Olga Vaksman; Helene Tuft Stavnes; Janne Kaern; Claes G Trope; Ben Davidson; Reuven Reich Journal: J Cell Mol Med Date: 2011-07 Impact factor: 5.310